Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin vs Silymarin + Vitamin E for Fatty Liver Disease
IRCT20241126063860N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Feb 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of empagliflozin, silymarin and vitamin e in steatosis (2 arms), sponsored by Arak University of Medical Sciences. Started Feb 2025; status: completed.
02
Drugs
empagliflozinsilymarinvitamin e
03
Conditions
steatosis
Beyond the preview
Go deeper on IRCT20241126063860N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241126063860N1.